Cargando…

Opportunities for preventing further endothelial dysfunction in pregnant COVID-19 patients with familial hypercholesterolemia

Detalles Bibliográficos
Autores principales:	Vuorio, Alpo, Kovanen, Petri T., Raal, Frederick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Lipid Association. Published by Elsevier Inc. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837469/ https://www.ncbi.nlm.nih.gov/pubmed/35232697 http://dx.doi.org/10.1016/j.jacl.2022.02.002

Ejemplares similares

Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2020)

Patients with familial hypercholesterolemia and COVID-19: Efficient and ongoing cholesterol lowering is paramount for the prevention of acute myocardial infarction
por: Kovanen, Petri T., et al.
Publicado: (2021)

Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2021)

Hospitalized Children With Familial Hypercholesterolemia and COVID-19: A Case for Preventive Anticoagulation
por: Vuorio, Alpo, et al.
Publicado: (2021)

Prevention of Cardiovascular Burden in COVID-19 Patients Suffering from Familial Hypercholesterolemia: A Global Challenge
por: Vuorio, Alpo, et al.
Publicado: (2021)

Familial hypercholesterolemia and statins in the COVID-19 era: Mitigating the risk of ischemic stroke
por: Vuorio, Alpo, et al.
Publicado: (2021)

Drug-drug interaction with oral antivirals for the early treatment of COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2023)

Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment
por: Vuorio, Alpo, et al.
Publicado: (2021)

Cholesterol-lowering drugs for high-risk hypercholesterolemia patients with COVID-19 while on Paxlovid™ therapy
por: Vuorio, Alpo, et al.
Publicado: (2022)

Monkeypox is a global public health emergency: The role of repurposing cholesterol lowering drugs not to be forgotten
por: Vuorio, Alpo, et al.
Publicado: (2022)

Long-Term Cardiovascular and Cerebrovascular Challenges Posed by COVID-19 in Patients With Familial Hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2022)

Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition
por: Vuorio, Alpo, et al.
Publicado: (2021)

Coronary microcirculatory dysfunction in hypercholesterolemic patients with COVID-19: potential benefit from cholesterol-lowering treatment
por: Vuorio, Alpo, et al.
Publicado: (2023)

Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters
por: Vuorio, Alpo, et al.
Publicado: (2018)

Comment on: “Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry”
por: Vuorio, Alpo, et al.
Publicado: (2021)

Wildfire smoke exposure and cardiovascular disease—should statins be recommended to prevent cardiovascular events?
por: Vuorio, Alpo, et al.
Publicado: (2023)

Hypercholesterolemia and COVID-19: Statins for Lowering the Risk of Venous Thromboembolism
por: Vuorio, Alpo, et al.
Publicado: (2021)

Elevated Lipoprotein(a) and Cerebral Venous Sinus Thrombosis in COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2021)

Inhibition of hepatic microsomal triglyceride transfer protein – a novel therapeutic option for treatment of homozygous familial hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2014)

Mucormycosis and glucose‐regulated protein 78 in COVID‐19: Amenable to statin treatment?
por: Vuorio, Alpo, et al.
Publicado: (2021)

SARS-CoV-2 reinfection: Adding insult to dysfunctional endothelium in patients with atherosclerotic cardiovascular disease
por: Kovanen, Petri T., et al.
Publicado: (2023)

Statins as Adjuvant Therapy for COVID-19 to Calm the Stormy Immunothrombosis and Beyond
por: Vuorio, Alpo, et al.
Publicado: (2021)

Editorial: Genetics of Familial Hypercholesterolemia: New Insight
por: Vuorio, Alpo, et al.
Publicado: (2021)

Continuation of fibrate therapy in patients with metabolic syndrome and COVID-19: a beneficial regime worth pursuing
por: Vuorio, Alpo, et al.
Publicado: (2022)

Editorial: Genetics of familial hypercholesterolemia: New insight—Volume II
por: Vuorio, Alpo, et al.
Publicado: (2022)

Compliance of the aorta in two diseases affecting vascular elasticity, familial hypercholesterolemia and diabetes: a MRI study
por: Soljanlahti, Sami, et al.
Publicado: (2008)

Aorta of young and middle-aged heterozygous familial hypercholesterolemia patients shows no functional or morphological impairment assessed by MRI
por: Soljanlahti, Sami, et al.
Publicado: (2008)

Gradual dose Titration of Lomitapide may Prevent Therapeutic Delays in Patients with Homozygous Familial Hypercholesterolemia
por: Harada-Shiba, Mariko, et al.
Publicado: (2023)

Collaboration between Family Physicians and Specialists in the Diagnosis and Management of Familial Hypercholesterolemia
por: Kotani, Kazuhiko
Publicado: (2021)

Cutaneous Xanthomas in a Young Child: Familial Hypercholesterolemia
por: Kumar, Sawan, et al.
Publicado: (2017)

Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy
por: Raal, Frederick, et al.
Publicado: (2013)

COVID-19 and Erectile Dysfunction: Endothelial Dysfunction and Beyond
por: Sansone, Andrea, et al.
Publicado: (2021)

LDL apheresis in a woman with severe heterozygous familial hypercholesterolemia. Late, but not too late
por: Mickiewicz, Agnieszka, et al.
Publicado: (2015)

The Necessity of Collaboration With Doctors Involved in Annual Medical Checkups in the Identification of Familial Hypercholesterolemia in Japan
por: Kakehi, Eiichi, et al.
Publicado: (2022)

Characterization of coronary atherosclerotic plaques in a homozygous familial hypercholesterolemia visualized by optical coherence tomography
por: Liu, Ze-Sen, et al.
Publicado: (2018)

Endothelial Microparticles as Potential Biomarkers in the Assessment of Endothelial Dysfunction in Hypercholesterolemia
por: Nik Ibrahim, Nik Nor Izah, et al.
Publicado: (2022)

Retrospective analysis of cohort database: Phenotypic variability in a large dataset of patients confirmed to have homozygous familial hypercholesterolemia
por: Raal, Frederick J., et al.
Publicado: (2016)

Opisthorchiasis, hypercholesterolemia, and cholangiocarcinoma: A reappraisal
por: Joob, Beuy, et al.
Publicado: (2017)

The red blood cell as a mediator of endothelial dysfunction in patients with familial hypercholesterolemia and dyslipidemia
por: Mahdi, Ali, et al.
Publicado: (2022)

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
por: Ginsberg, Henry N., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sob9sok6uredn4j2gr78790034